CICC: Raises Akeso (09926.HK) target price by 8.3% to HK$130, maintains "Outperform" rating.

Zhitong Finance APP has learned that CICC released a research report stating that Akeso (09926.HK) announced that AK112, under the trade name Yidafang, compared with pembrolizumab for first-line treatment of PD-L1-positive NSCLC in the registrational Phase III clinical trial (HARMONI-2) showed significantly positive OS results at WCLC. Considering the impressive H2 data, the bank raised the probability of success for the overseas H7 clinical trial, maintained its 2026 and 2027 profit forecasts unchanged, maintained the "Outperform Industry" rating, and raised the target price by 8.3% to HKD 130.